Can an adult with moderate-to-severe plaque psoriasis refractory to topical therapy use Taltz (ixekizumab), and what is the dosing schedule and required pre‑treatment screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Taltz (Ixekizumab) for Moderate-to-Severe Plaque Psoriasis

Yes, Taltz (ixekizumab) is strongly recommended for adults with moderate-to-severe plaque psoriasis refractory to topical therapy, with a Grade A recommendation from the 2019 AAD-NPF guidelines. 1

Eligibility and Indication

Taltz is FDA-approved and guideline-recommended for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy 21. This explicitly includes patients who have failed topical treatments, making it an appropriate next-step option.

Dosing Schedule

Induction Phase (Weeks 0-12)

  • Week 0: 160 mg (two 80 mg subcutaneous injections)
  • Weeks 2,4,6,8,10, and 12: 80 mg subcutaneous injection at each visit 221

Maintenance Phase (After Week 12)

  • Standard maintenance: 80 mg every 4 weeks 221
  • Alternative for inadequate responders: Some patients may require 80 mg every 2 weeks to maintain response 13

Important clinical pearl: Among patients who don't achieve clear or almost clear skin (sPGA ≤1) by week 12, continuing every-2-week dosing beyond 12 weeks results in significantly better outcomes at week 52 compared to switching to every-4-week dosing (64% vs 36% achieving clear/almost clear skin) 4.

Required Pre-Treatment Screening

Mandatory Testing Before Initiation 22:

Tuberculosis screening:

  • Evaluate for active and latent TB infection
  • Do NOT initiate Taltz in patients with active TB
  • Treat latent TB before starting ixekizumab

Vaccinations:

  • Complete all age-appropriate vaccinations per current immunization guidelines before initiating treatment
  • This is critical as live vaccines should not be given during treatment

Additional Baseline Monitoring (Expert Consensus) 1:

  • Complete blood count (CBC)
  • Complete metabolic panel (CMP)
  • Chest radiograph if TB test is positive
  • Consider infectious disease consultation for active infections

Efficacy Expectations

The evidence supporting ixekizumab is robust, with multiple Phase III RCTs demonstrating superior efficacy 11:

  • Rapid onset: Clinical responses visible as early as week 1 5
  • High clearance rates: 78-93% of patients achieve PASI 75 through 108 weeks 6
  • Sustained response: Efficacy maintained through long-term treatment (60-108 weeks) 67

Special Populations and Considerations

Scalp psoriasis: Grade B recommendation - 78% complete resolution by week 48 1

Nail psoriasis: Grade B recommendation - 51% complete resolution by week 48 1

Erythrodermic psoriasis: Grade B recommendation 1

Generalized pustular psoriasis: Grade B recommendation 1

Psoriatic arthritis: Grade A recommendation - can be used as monotherapy or combined with conventional DMARDs like methotrexate 1

Safety Considerations and Contraindications

Absolute contraindications 1:

  • History of allergic reaction to ixekizumab or vehicle

Relative contraindications/cautions 11:

  • Active infection or sepsis (consult infectious disease before initiating)
  • Untreated hepatitis B infection
  • History of lymphoreticular malignancy
  • Inflammatory bowel disease (IBD): Avoid IL-17 inhibitors in patients with personal history of or active IBD due to risk of reactivation/worsening 11

Common adverse events 11:

  • Increased risk of infections, particularly mucocutaneous Candida infections
  • Most treatment-emergent adverse events are mild to moderate (85%) 6
  • Low discontinuation rate due to adverse events (6.4%) 6

Immunogenicity: Neutralizing anti-ixekizumab antibodies can develop and are associated with reduced drug concentrations and loss of efficacy 11

Combination Therapy

While there are no published reports of combination therapy with topicals or systemic agents, there is no reason to consider such combinations unsafe 11. This provides flexibility for augmenting treatment in partial responders.

Treatment Response Assessment

Assess definitive response (positive or negative) after 12 weeks of continuous therapy 1. For partial responders at week 12, consider:

  • Dose escalation to every-2-week maintenance dosing
  • Addition of topical corticosteroids or vitamin D analogues
  • Addition of other systemic agents (though evidence is limited)

References

5
Research

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

American journal of clinical dermatology, 2017

Related Questions

What is the recommended dosing regimen of Taltz (ixekizumab) for plaque psoriasis in adults and pediatric patients?
Can Taltz (ixekizumab) be administered every other month?
In a patient with chronic plaque psoriasis receiving risankizumab (Skyrizi), is it acceptable to give only two doses of hepatitis B vaccine?
For a 28-year-old unmarried male with moderate-to-severe plaque psoriasis, is secukinumab or ustekinumab the preferred biologic therapy?
What is the recommended dosing, screening, and safety monitoring for Skyrizi (risankizumab) in an adult with moderate-to-severe plaque psoriasis who has failed conventional systemic therapy?
How should oxcarbazepine (Trileptal) be initiated and titrated in an adult patient?
Which of the following is NOT an indication for referral to a specialized asthma clinic: occupational asthma, difficulty controlling symptoms, use of oral prednisone more than twice per year or hospitalization, ethanol use, or smoking cessation?
Should testosterone be given subcutaneously rather than intramuscularly in an adult male with primary or secondary hypogonadism?
When is Trileptal (oxcarbazepine) used in psychiatry?
How do squamous mucosa and respiratory mucosa differ in structure and function?
Which diuretic is appropriate for a patient with an estimated glomerular filtration rate (eGFR) of 37 mL/min?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.